Core Insights - Creative Medical Technology Holdings, Inc. has received two U.S. patents for its ImmCelz™ platform, focusing on treatments for Type 1 Diabetes and heart failure, leveraging supercharged Regulatory T cells [2][3] - The recent Nobel Prize awarded to researchers in Treg science highlights the significance of the company's research focus and its potential impact on regenerative immunotherapy [1][3] Patent Details - U.S. Patent Number 12931925B2, expiring on May 24, 2043, covers the prevention and treatment of Type 1 Diabetes through the enhancement of myeloid suppressor cell activity [2] - U.S. Patent Number 12385011B2, expiring on December 15, 2042, pertains to the treatment of heart failure and post-infarct pathological remodeling using ex vivo reprogrammed immune cells [2] Market Potential - The heart failure treatment program targets over five million patients in the U.S. at risk of heart failure, with an additional six million patients suffering from refractory angina potentially eligible for treatment [3] - The Type 1 diabetes program supports a broad, cell-based immunotherapy approach validated with cells from Type 1 diabetes patients, aligning with the ongoing CREATE-1 clinical trial [4] Technology Overview - The ImmCelz™ platform reprograms a patient's immune cells outside the body, enhancing them with optimized cell-free factors before reintroducing them, aiming to facilitate tissue repair rather than merely suppressing symptoms [5][6] - This innovative approach positions the company to address high-burden medical conditions where immune over-activation and tissue damage are prevalent [5] Company Profile - Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicine solutions across various indications, utilizing advanced cell therapy technologies to improve patient outcomes [7]